Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma

Relapsed Mantle cell lymphoma (MCL) is often treated with Bruton’s tyrosine kinase inhibitors (BTKi); however, post-BTKi relapse can be challenging. Adding venetoclax (VEN) to ibrutinib (IBR) has shown synergy in preclinical MCL models. Prior MCL studies of the combination show promising efficacy bu...

Descripción completa

Detalles Bibliográficos
Autores principales: Portell, Craig A., Wages, Nolan A., Kahl, Brad S., Budde, Lihua E., Chen, Robert W., Cohen, Jonathon B., Varhegyi, Nikole E., Petroni, Gina R., Williams, Michael E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905688/
https://www.ncbi.nlm.nih.gov/pubmed/34700344
http://dx.doi.org/10.1182/bloodadvances.2021005357

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905688/
https://www.ncbi.nlm.nih.gov/pubmed/34700344
http://dx.doi.org/10.1182/bloodadvances.2021005357

Ejemplares similares